



## Metrion Biosciences listed in The Sunday Times 100 Tech, as one of Britain's fastest-growing private technology companies

- *Inaugural feature recognises companies within the UK technology sector, developing or selling a proprietary technology*
- *Listing is recognition of Metrion's leadership position in preclinical ion channel drug discovery research services*

**Cambridge, UK, 20 January 2025:** Metrion Biosciences ("Metrion"), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced it has been listed in The Sunday Times 100 Tech, Britain's fastest-growing private technology companies. The inaugural feature, published 19<sup>th</sup> January, highlights the UK's fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.

Metrion provides preclinical drug discovery services to a growing network of major pharmaceutical companies and smaller drug discovery businesses in leading global markets, including Europe, USA and Asia. The Company's offering leverages more than a decade of specialist ion channel research, built upon pioneering work to develop and use automated patch clamp technology in drug discovery. Its suite of advanced, proprietary assays and cell lines, available to customers via standard or bespoke research projects, provide high-quality data for a range of applications, including *in vitro* cardiac safety, high-throughput ion channel screening, phenotypic assays and neuroscience research using brain slice tissue and an array of primary neurones. The Company offers careful interpretation of experimental findings, providing strategic recommendations to support decision making to best inform screening strategy.

Following the closing of the Company's £3.7m equity financing in December 2023, Metrion invested heavily into scaling up operations throughout 2024 to meet growing global demand for its specialist ion channel, cardiac safety and neuroscience drug discovery services. As part of this, the Company made a series of strategic appointments to drive commercial expansion, with Lee Patterson joining as CEO<sup>1</sup> in December 2024, Dr Chris Mathes as Chief Commercial Officer<sup>2</sup> in July 2024, and Clare Ruttly's promotion to Chief Financial Officer in December 2023<sup>3</sup>.

*"Metrion is proud to celebrate our 10-year anniversary this year, during which time the Company has established itself as a valued and trusted global partner for preclinical drug discovery. Being selected for the 100 Tech listing underscores our success, as we continue to expand and meet the growing demand for our services," commented Lee Patterson, CEO, Metrion Biosciences: "I would like to thank The Sunday Times for this recognition, as well as our investors, partners and most importantly our hard-working, dedicated team for their unwavering support in our mission to transform our partners' R&D programs, making meaningful contributions to advance human health."*

1. *Press Release (25<sup>th</sup> November, 2024): [Metrion Biosciences appoints Lee Patterson as CEO](#)*
2. *Press Release (23<sup>rd</sup> July, 2024): [Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer](#)*
3. *Press release (11<sup>th</sup> March, 2024): [Metrion Biosciences strengthens team with 3 key appointments](#)*

-ENDS-

## Notes to Editors



*Lee Patterson, CEO,  
Metrion Biosciences*

For high resolution images please contact Zyme Communications

### **For further information please contact:**

Katie Odgaard  
Zyme Communications  
E-mail: [katie.odgaard@zymecommunications.com](mailto:katie.odgaard@zymecommunications.com)  
Tel: +44 (0)7787 502 947

*To opt-out from receiving press releases from Zyme Communications please email [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#)*

Sue Pepper  
Metrion Biosciences  
E-mail: [sue.pepper@metrionbiosciences.com](mailto:sue.pepper@metrionbiosciences.com)

To opt-out from receiving press releases from Metrion Biosciences please email [sue.pepper@metrionbiosciences.com](mailto:sue.pepper@metrionbiosciences.com). View our [privacy notice](#).

### **About Metrion Biosciences**

Metrion Biosciences is a specialist preclinical drug discovery contract research organization (CRO) and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays including an industry leading panel of *in vitro* cardiac safety assays, high-throughput screening, and translational research such as native cell and phenotypic assays for neurological and cardiotoxicity testing. Metrion also provides neuroscience focused assays with brain slices, DRG neurons, and other primary neurons.

Metrion's leadership has extensive and in-depth experience, offering careful interpretation of experimental findings, communicating results and providing strategic recommendations to support decision making to best inform screening strategy. Acting as an extension of our clients' research teams, Metrion provides tailored assay formats, quality assured data packages and traditional or bespoke and novel studies on a fee-for-service or collaboration basis.

For more information, please visit [www.metrionbiosciences.com](http://www.metrionbiosciences.com)  
LinkedIn: [@metrion-biosciences](#) | X: [@metrion\\_biosci](#)